Overview

Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer

Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
This study is designed to test the efficacy and safety of total neoadjuvant induction and consolidation CapeOX plus neoadjuvant intensity modulated radiotherapy with concurrent capecitabine for MRI defined high-risk rectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Beijing Cancer Hospital
Treatments:
Capecitabine
Oxaliplatin